Implantable Cardiac Monitors in High-Risk Post-Infarction Patients With Cardiac Autonomic Dysfunction (SMART-MI)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02594488|
Recruitment Status : Completed
First Posted : November 3, 2015
Last Update Posted : June 23, 2021
The majority of deaths after myocardial infarction occurs in patients with preserved left ventricular ejection fraction (>35%) for whom no prophylactic strategies exist. Periodic Repolarization Dynamics (PRD) and Deceleration Capacity (DC) of heart rate are autonomic risk markers that identify a new high risk group of patients with LVEF 35-50% who have the same poor prognosis as patients with LVEF ≤35%.
In SMART-MI, post-infarction patients with LVEF 35-50% and abnormal PRD and/or DC will be randomly assigned to biomonitoring-guided therapy or conventional follow-up.
|Condition or disease||Intervention/treatment||Phase|
|Myocardial Infarction Autonomic Nervous System Diseases||Device: Medtronic Reveal LINQ implantable cardiac monitor||Not Applicable|
Sudden cardiac death (SCD) is the most common single cause of death in the industrialized world. Patients after myocardial infarction (MI) are at increased risk of SCD. Current guidelines recommend prophylactic ICD-implantation in post-MI patients with reduced left ventricular ejection fraction (LVEF ≤35%). However, the majority of arrhythmic deaths after MI occurs in patients with LVEF >35% in whom no specific prophylactic strategies exist, indicating an important unmet medical need.
There is a large body of evidence that presence of cardiac autonomic dysfunction after MI is associated with an increased susceptibility to malignant brady- and tachyarrhythmias eventually culminating in SCD. Periodic repolarization dynamics (PRD) and heart rate deceleration capacity (DC) are clinically validated autonomic risk markers that provide strong and independent prognostic information in post-MI patients with LVEF >35%. PRD and DC reflect different facets of autonomic function and can therefore be used in combination to predict risk. Previous studies demonstrated that combined assessment of PRD and DC identifies a new high-risk group among post-MI patients with moderately reduced LVEF (36-50%). This new high-risk group has similar characteristics with respect to prognosis and patient numbers as the established high-risk group identified by LVEF ≤35%.
However, the exact mechanisms leading to death in this new high-risk group need to be investigated in order to develop specific preventive strategies. As known from studies with implantable cardiac monitors (ICM) in post-MI patients with LVEF ≤40% eventual death is often preceded by primarily asymptomatic serious arrhythmic events. These data suggest a potential time frame for pre-emptive interventions in case of arrhythmic events, which could improve outcome.
Therefore, SMART-MI will assess the occurrence and prognostic implications of serious arrhythmic events in this newly identified high-risk group by remote monitoring with ICM. Survivors of acute MI (<40 days) and LVEF 36-50% undergo autonomic testing for presence of abnormal PRD and/or DC. Those with autonomic dysfunction will be randomly assigned to ICM-implantation or conventional follow-up. Superiority of ICMs in detection of predefined serious arrhythmic events will be tested based on a time-to-event analysis. A central ICM core lab will be implemented allowing for a response to arrhythmias within 48h. The effect of remote monitoring on clinical outcomes will be tested as secondary endpoints. The study will provide the rationale for a future guideline-relevant study testing prophylactic therapies in this newly identified high-risk group.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||400 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Implantable Cardiac Monitors in High-risk Post-infarction Patients With Cardiac Autonomic Dysfunction and Moderately Reduced Left Ventricular Ejection Fraction|
|Actual Study Start Date :||May 6, 2016|
|Actual Primary Completion Date :||February 2021|
|Actual Study Completion Date :||February 2021|
Active Comparator: Remote monitoring
Remote cardiac monitoring by the Reveal® LINQ implantable cardiac monitor
Device: Medtronic Reveal LINQ implantable cardiac monitor
The implantable cardiac monitor is implanted under the skin in the region of the thorax. It continuously monitors the heart's electrical activity for up to three years. Predefined arrhythmias are daily transmitted to a central core lab. In case of arrhythmias, specific guideline-based treatment is initiated within 48h.
No Intervention: Control arm
Follow-up at the same frequency, but with no implantable cardiac monitor
- Detection of serious arrhythmic events [ Time Frame: 18 months ]Time to detection of one of the following serious arrhythmic events: atrial fibrillation ≥6 min, higher degree AV-block ≥ IIb, ventricular tachycardia with a cycle length ≤320ms lasting for ≥12 sec (corresponding to 40 beats), sustained ventricular tachycardia and ventricular fibrillation
- Composite of all-cause mortality, stroke, systemic arterial thromboembolism and unplanned hospitalizations for decompensated heart failure [ Time Frame: 18 months ]Time to one of following clinical events: death, stroke, systemic arterial thromboembolism and unplanned hospitalization for decompensated heart failure
- All cause mortality [ Time Frame: 18 months ]Time to death
- Cardiovascular mortality [ Time Frame: 18 months ]Time to cardiovascular death
- Unplanned hospitalizations for decompensated heart failure [ Time Frame: 18 months ]Time to unplanned hospitalizations for decompensated heart failure
- Sinus arrest >6sec [ Time Frame: 18 months ]Time to detection of sinus arrest >6sec
- Atrial fibrillation ≥6 min [ Time Frame: 18 months ]Time to detection of atrial fibrillation ≥6 min
- Higher degree AV-block ≥ IIb [ Time Frame: 18 months ]Time to detection of higher degree AV-block ≥ IIb
- Non-sustained ventricular tachycardia [ Time Frame: 18 months ]Time to detection of ventricular tachycardia with a cycle length ≤320ms lasting for ≥12 sec
- Sustained ventricular tachycardia / ventricular fibrillation [ Time Frame: 18 months ]Time to detection of sustained ventricular tachycardia / ventricular fibrillation
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02594488
|Principal Investigator:||Axel Bauer, MD||LMU Klinikum|
|Principal Investigator:||Stefan Kaeaeb, MD||LMU Klinikum|
|Study Chair:||Steffen Massberg, MD||LMU Klinikum|